Clinical Observation And Mechanism Function, Oxidative Stress And Blood GLP-1 Level Of Type 2 β Cells In The Diabetic Patient's SQC In Combination With Insulin

There are two parts in this paper.One part is reference review of diabetes,The other part is clinical research on the treatment for Shenqi Compound Extract combined with insulin therapy in type2diabetic patients.Reference reviewIn reference review part of this paper, from the perspective of traditional Chinese medicine, the understanding of diabetes, etiology and pathogenesis, syndrome differentiation and treatment system are described.clinical researchObjective:To investigate the effects of Shenqi Compound Extract combined with insulin therapy on islet B cell function,especially on early phase of insulin secretion, oxidative stress and on the secretion of glucagon-like peptide-1(GLP-1)in type2diabetic patients who need to use insulin therapy to control bloodglucose.Methods:Type2diabetic patients who need to use insulin therapy were selected. One is study group and the other is control group. The study group injected insulin and combined with Shenqi Compound Extract orally, the control group only used insulin.This study lasted for12weeks. At baseline and the end of the study,Oral glucose tolerance test(100g standards bread)+C-peptide release test was performed,respectively. Other indices such as plasma glucose,C-peptide,serum GLP-1(0h,0.5h,2h),and HbA1c,total cholesterol(TC),triglycerides(TG), high density lipoprotein cholesterol(HDL-ch) and low density lipoprotein cholesterol(LDL-ch),none stesterified fatty acid (NEFA),total superoxide dismutase(T-SOD),malondialdehyde(MDA),soluble E-selectin (sE-selectin),soluble vascular cell adhesion molecule-1(sVC AM-1),prothrombin time(PT),activated partial thromboplastin (APTT),fibrinogen(Fib),hemoglobin,liver and kidney function were detected. Use ΔCP30/ΔG30to evaluate the early phase of βcell function. Calculated HOMA-β, HOMA-IR to reflect the pancreatic beta cell function and insulin resistance(IR).Results:Fourty two patients were included in the study and fourty patients finished follow-up. At baseline, the two groups of patients with general information and observations through the statistical analysis were not statistically different (p>0.05).Either the study group or the control group of each point plasma glucose significantly decreased, HbAlc is also significantly decreased[(10.97±1.23vs7.71±1.01)%, p<0.05].After the study, compared with before the study,0.5hC-p of the study group increased[(0.86±0.42vs1.59±0.54)nmol/L,p=0.000] significantly Δ CP30/Δ G30of the study group increased (0.07±0.48vs0.53±0.51,p=0.01) significantly,too.In the control group these indices did not change significantly.0hGLP-1,0.5hGLP-1,2hGLP-1of the study group increased all. T-SOD activity of the study group were improved. Other indices of the study group,such as MDA levels,sE-selectin,sVCAM-1,TG、LDL-C were decreased significantly. NEFA decreased[(242.85±252.21vs566.80±476.33)ng/mL,p=0.000]too. No significant changes in the lipids of the control group. The level of PT,APTT of the study group had shorter than that of the control group. The level of Plasma TG,LDL-C,Fib of the study group were decreased. No significant changes in HDL-c.HOMA-B,HOMA-IR, regardless of the study group or the control group showed no significant difference.Conclusion:Single-use insulin to control blood sugar in type2diabetic patients,12weeks Shenqi Shenqi Compound Extract treatment can significantly improve the clinical symptoms and signs of these patients, control blood glucose,improve HbAlc compliance rate, improve Bcell function.Effects of Shenqi Compound Extract on these function in type2diabetic patients may relate to the improvement of IR,improvement of lipid metaboli-sm disorders, improvement of Coagulation function,increasing of postprandial GLP-1secretion, especially in the early phase of GLP-1secretion,decreasing in oxidative stress,improvement of the anti-oxidation, improvement of endothelial function.